Merck Prevails in Singular Patent Infringement Lawsuit
MRK | Quote | Chart | News | PowerRating -- Merck & Co., Inc. announced that the U.S. District Court for the District of New Jersey has ruled in Merck's favor in a patent infringement suit against Teva Pharmaceuticals USA Inc.
According to a release, Teva was seeking FDA approval to sell a generic version of 4, 5 and 10 mg tablets of Singular (montelukast sodium), Merck's asthma and allergic rhinitis medicine.
In his decision, Judge Garrett E. Brown upheld Merck's patent on Singular and ruled that Teva committed infringement. Judge Brown also issued an injunction blocking the approval of Teva's generic versions until the August 2012 expiration of the patent.
"The court appropriately ruled that the patent for Singular in the U.S. is valid," said Bruce Kuhlik, executive vice president and general counsel of Merck. "We invest heavily in the R&D that is needed to discover innovative medicines like Singular, and we will vigorously defend our intellectual property rights."
Merck filed the patent infringement lawsuit against Teva in February 2007. The trial was heard before Judge Brown in February.
((Comments on this story may be sent to health@closeupmedia.com))
For full details on Merck & Co (MRK) MRK. Merck & Co (MRK) has Short Term PowerRatings at TradingMarkets. Details on Merck & Co (MRK) Short Term PowerRatings is available at This Link.
- AnaptysBio announces collaboration with Merck - 02/09/10
- Critical Alerts for Merck, Lowe's, MEMC Electronic Materials, Lennar, and Kinross Gold Released by Seven Summits Research - 02/09/10
- Ligand Announces Fourth Quarter and Full Year 2009 Consolidated Financial Results - 02/09/10
- Emerging Combination Agent from Merck Will Garner Peak Year Sales of More Than $250 Million for the Treatment of Asthma - 02/08/10
- AnaptysBio Announces Strategic Collaboration with Merck & Co., Inc. - 02/08/10
- More News >>
